Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test

European Urology

Volumn 58, Issue 4, 2010, Pages 475-481

  Roobol, Monique J ^a   Schröder, Fritz H ^a   Van Leeuwen, Pim ^a   Wolters, Tineke ^a   Van Den Bergh, Roderick C N ^a   Van Leenders, Geert J L H ^a   Hessels, Daphne ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Detection; PCA3; Performance characteristics; Prostate cancer; Prostate specific antigen (PSA)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER ANTIGEN 3 GENE; RELIABILITY;

AGED; ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77956535473     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.06.039     Document Type: Article

References (25)

1. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
2. PCA3-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 16 discussion 15-6
3. J.B. De Kok, G.W. Verhaegh, and R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
4. PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer Eur Urol 46 2004 182 187 discussion 187
5. M.P. Van Gils, E.B. Cornel, and D. Hessels Molecular PCA3 diagnostics on prostatic fluid Prostate 67 2007 881 887
6. J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA. PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089 1095
7. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535
8. I.M. Thompson, D.P. Ankerst, and C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66 70 (Pubitemid 41002840)
9. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
10. M.J. Roobol, W.J. Kirkels, and F.H. Schröder Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands) BJU Int 92 Suppl 2 2003 48 54
11. R. Kranse, P.M.M. Beemsterboer, J.B.W. Rietbergen, D. Habbema, J. Hugosson, and F.H. Schröder Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region) Prostate 39 1999 316 322 (Pubitemid 29244508)
12. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
13. M.P. Van Gils, D. Hessels, and O. van Hooij The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance Clin Cancer Res 13 2007 939 943
14. Boevee S, Venderbos LDF, Ranniko A, et al. Change of treatment over time in both arms of the ERSPC. Eur J Cancer. In press.
15. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
16. W.J. Catalona, D.S. Smith, and D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
17. D. Hessels, M.P. van Gils, and O. van Hooij Predicitve value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10 16
18. D. Schilling, T. de Reijke, B. Tombal, A. de la Taille, J. Hennenlotter, and A. Stenzl The prostate cancer gene 3 assay: indications for use in clinical practice BJU Int 105 2010 452 455
19. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978 discussion 1978-9
20. M.P. Van Gils, D. Hessels, and C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215 1222
21. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809 discussion 1809-10
22. F.K. Chun, A. de la Taille, and H. van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 668
23. D.P. Ankerst, J. Groskopf, and J.R. Day Predicting prostate cancer risk through incorporation of prostate cancer gene 3 J Urol 180 2008 1303 1308 discussion 1308
24. Roobol MJ, Hessels D, Vickers A, et al. Predicting prostate biopsy outcome in a screening setting. PSA, PCA3, a kallikrein panel, the risk calculator or a combination? ERSPC Rotterdam. Poster 974 presented at: European Association of Urology Annual Congress; April 16-20, 2010; Barcelona, Spain.
25. A.J. Vickers, A.M. Cronin, and M.J. Roobol A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam Clin Cancer Res 16 2010 3232 3239